07.20.22
Rank: #15 (Last year: #12)
€7.86 Billion ($8.90 Billion)
Prior Fiscal: €7.42 Billion
Percentage Change: +5.8%
R&D Expenditure: €316M
No. of Employees: 66,234
Global Headquarters: Melsungen, Germany
KEY EXECUTIVES:
Anna Maria Braun, LL.M., CEO, Region Asia Pacific, Avitum Division, B. Braun
Markus Strotmann, Member of the Board, Hospital Care Division, B. Braun
Jean-Claude Dubacher, Chairman and CEO, B. Braun of America
James Allen, SVP and CFO, B. Braun of America
Juergen Schloesser, SVP and COO, B. Braun of America
Chuck DiNardo, President, Aesculap
B. Braun posted a rise in sales last year, growing 5.8% to €7.43 billion. All three business divisions posted revenue increases, with the Aesculap division showing the most growth. The Hospital Care division generated €4.12 billion in 2021, rising 5.1% from the previous year. Germany, Latin America, and North America were the major sales drivers, followed by Eastern Europe and Switzerland. High infusion pump and accessories sales drove growth in Germany, Great Britain, and the U.S.; however, sales in China were reduced due to price reductions. Growth was in the double digits in other Asia-Pacific markets like Japan, Australia, and Thailand.
Last February, the business earned U.S. Food and Drug Administration (FDA) approval for its Acetaminophen injection available in multiple doses. Available in sturdy, flexible PAB IV Bags in both 1,000 mg in 100 mL and 500 mg in 50 mL doses, the injection is manufactured using dual-sourced active pharmaceutical ingredients to mitigate potential supply risks.
B. Braun unveiled its Peripheral Advantage program to improve patients’ peripheral intravenous (IV) therapy experience last April. The program combines clinical instruction, data-driven insights, and advanced tools so nurses can achieve first-stick success and prevent many complications related to peripheral IV therapy. Real-word data is collected throughout to provide baseline and ongoing insights and analytics to help gauge the program’s impact on patient satisfaction, first stick success, IV catheter dwell time, and cost containment. Professional on-site clinical instruction and a complete set of cutting-edge tools are also included.
September saw the launch of CARESAFE IV administration sets with an optional AirStop component. According to B. Braun, they are the first robust IV administration set portfolio not made with polyvinyl chloride (PVC) and diethylhexyl phthalate (DEHP). The sets protect the enviromnment and reduce patient exposure to toxic substances. They also help protect from risks related to air infusion and help prevent the line from running dry—the AirStop filter only allows fluid to pass through.
In December came the release of the next-gen OnGuard 2 closed system transfer device (CTSD) to prevent escape of hazardous drugs into the environment. Enhancements made include modifications to material composition intended to increase compatibility with known hazardous drugs, as well as extended microbial ingress claim for the vial adaptor for up to a week.
A few days later, the division unveiled a portfolio of Magnesium Sulfate ready-to-use injectable drug products. The release aims to ensure the reliable supply of a leading drug for prevention and control of seizures associated with preeclampsia and eclampsia.
The Aesculap division posted an 8.6% increase last year with proceeds of €1.87 billion. The division has recovered from 2020’s poor performance caused by COVID-19, but hasn’t yet reached its pre-pandemic level. The repeated elective procedure postponement caused knee, hip, and spine implant sales to be below the company’s expectations—felt particularly in the German, Turkish, Vietnamese, and Malaysian markets. The U.S., China, Australia, Spain, and Russia experienced growth in containers, minimally invasive surgery, angioplasty, and access port product sales.
The company’s Interventional Systems business began a collaboration last March with Infraredx, a Nipro Company, to accelerate the FDA IDE trial for the SeQuent Please ReX drug-coated PTCA balloon catheter. The trial is studying treatment of coronary in-stent restenosis—gradual re-narrowing of a coronary artery after stent implantation. Both will pool clinical expertise and financial resources to execute the study.
The division entered a partnership with REVA Medical to distribute REVA’s Fantom Encore bioresorbable scaffold for coronary interventions in November, beginning in Germany and Switzerland. The bioresorbable scaffold offers a reliable, sustainable solution for patients who require temporary physical vessel support.
The Avitum division’s 2021 sales rose 5.7%, reaching €1.83 billion. Extracorporeal blood treatment sales were strong. The main growth markets were China, the U.S., and Italy according to the company’s annual report. Wound management and ostomy and continence care products expanded as well, and demand for infection control products remained high. Rising purchase prices and supplier delivery issues hampered the business’s growth.
B. Braun Medical Inc. made two executive changes last year as well—former Steel Partners CFO James Allen replaced the retiring Bruce Heugel as senior VP and CFO in last May, and Jennifer Prioleau succeeded retiring Cathy Codrea as senior VP, chief legal officer, and chief compliance officer last fall.
€7.86 Billion ($8.90 Billion)
Prior Fiscal: €7.42 Billion
Percentage Change: +5.8%
R&D Expenditure: €316M
No. of Employees: 66,234
Global Headquarters: Melsungen, Germany
KEY EXECUTIVES:
Anna Maria Braun, LL.M., CEO, Region Asia Pacific, Avitum Division, B. Braun
Markus Strotmann, Member of the Board, Hospital Care Division, B. Braun
Jean-Claude Dubacher, Chairman and CEO, B. Braun of America
James Allen, SVP and CFO, B. Braun of America
Juergen Schloesser, SVP and COO, B. Braun of America
Chuck DiNardo, President, Aesculap
B. Braun posted a rise in sales last year, growing 5.8% to €7.43 billion. All three business divisions posted revenue increases, with the Aesculap division showing the most growth. The Hospital Care division generated €4.12 billion in 2021, rising 5.1% from the previous year. Germany, Latin America, and North America were the major sales drivers, followed by Eastern Europe and Switzerland. High infusion pump and accessories sales drove growth in Germany, Great Britain, and the U.S.; however, sales in China were reduced due to price reductions. Growth was in the double digits in other Asia-Pacific markets like Japan, Australia, and Thailand.
Last February, the business earned U.S. Food and Drug Administration (FDA) approval for its Acetaminophen injection available in multiple doses. Available in sturdy, flexible PAB IV Bags in both 1,000 mg in 100 mL and 500 mg in 50 mL doses, the injection is manufactured using dual-sourced active pharmaceutical ingredients to mitigate potential supply risks.
B. Braun unveiled its Peripheral Advantage program to improve patients’ peripheral intravenous (IV) therapy experience last April. The program combines clinical instruction, data-driven insights, and advanced tools so nurses can achieve first-stick success and prevent many complications related to peripheral IV therapy. Real-word data is collected throughout to provide baseline and ongoing insights and analytics to help gauge the program’s impact on patient satisfaction, first stick success, IV catheter dwell time, and cost containment. Professional on-site clinical instruction and a complete set of cutting-edge tools are also included.
September saw the launch of CARESAFE IV administration sets with an optional AirStop component. According to B. Braun, they are the first robust IV administration set portfolio not made with polyvinyl chloride (PVC) and diethylhexyl phthalate (DEHP). The sets protect the enviromnment and reduce patient exposure to toxic substances. They also help protect from risks related to air infusion and help prevent the line from running dry—the AirStop filter only allows fluid to pass through.
In December came the release of the next-gen OnGuard 2 closed system transfer device (CTSD) to prevent escape of hazardous drugs into the environment. Enhancements made include modifications to material composition intended to increase compatibility with known hazardous drugs, as well as extended microbial ingress claim for the vial adaptor for up to a week.
A few days later, the division unveiled a portfolio of Magnesium Sulfate ready-to-use injectable drug products. The release aims to ensure the reliable supply of a leading drug for prevention and control of seizures associated with preeclampsia and eclampsia.
The Aesculap division posted an 8.6% increase last year with proceeds of €1.87 billion. The division has recovered from 2020’s poor performance caused by COVID-19, but hasn’t yet reached its pre-pandemic level. The repeated elective procedure postponement caused knee, hip, and spine implant sales to be below the company’s expectations—felt particularly in the German, Turkish, Vietnamese, and Malaysian markets. The U.S., China, Australia, Spain, and Russia experienced growth in containers, minimally invasive surgery, angioplasty, and access port product sales.
The company’s Interventional Systems business began a collaboration last March with Infraredx, a Nipro Company, to accelerate the FDA IDE trial for the SeQuent Please ReX drug-coated PTCA balloon catheter. The trial is studying treatment of coronary in-stent restenosis—gradual re-narrowing of a coronary artery after stent implantation. Both will pool clinical expertise and financial resources to execute the study.
The division entered a partnership with REVA Medical to distribute REVA’s Fantom Encore bioresorbable scaffold for coronary interventions in November, beginning in Germany and Switzerland. The bioresorbable scaffold offers a reliable, sustainable solution for patients who require temporary physical vessel support.
The Avitum division’s 2021 sales rose 5.7%, reaching €1.83 billion. Extracorporeal blood treatment sales were strong. The main growth markets were China, the U.S., and Italy according to the company’s annual report. Wound management and ostomy and continence care products expanded as well, and demand for infection control products remained high. Rising purchase prices and supplier delivery issues hampered the business’s growth.
B. Braun Medical Inc. made two executive changes last year as well—former Steel Partners CFO James Allen replaced the retiring Bruce Heugel as senior VP and CFO in last May, and Jennifer Prioleau succeeded retiring Cathy Codrea as senior VP, chief legal officer, and chief compliance officer last fall.